Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 19Sarcoma 3

Conditions

Neurofibrosarcoma 3Neurofibromatosis 1 3Sarcoma 2Sarcoma, Kaposi 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

AZD 6244 3X-Rays 1Surgical Procedures, Operative 1Specimen Handling 1Sirolimus 1Radiotherapy 1Photons 1Magnetic Resonance Spectroscopy 1Liquid Biopsy 1Ifosfamide 1High-Energy Shock Waves 1Filgrastim 1Etoposide 1Doxorubicin 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × AZD 6244 × Sarcoma × Clear all
NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Sarcoma Alliance for Research through Collaboration

Phase 2 Completed
21 enrolled 12 charts
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

University of Alabama at Birmingham

Phase 2 Not yet recruiting
41 enrolled
CNSSarcoma

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT06735820 2025-07-03

MEKMDM2

Children's National Research Institute

Phase 1/2 Not yet recruiting
45 enrolled
CNSSarcoma

Neurofibromatosis 1, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡